Skip to main content
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
letter
. 1997 May;123(5):286–287. doi: 10.1007/BF01208640

The development of alkylphosphocholines as signal transduction inhibitors: experimental and clinical challenges

P Hilgard 1,, J Pohl 1, J Engel 1
PMCID: PMC12200075  PMID: 9201252

Abstract

Alkylphosphocholines are a new class of anticancer agents. Their mode of action is considered to be related to the inhibition of phospholipase C and protein kinase C. These enzymes play a major role in intracellular signalling pathways. Their inhibition by alkylphosphocholines leads in the dimethylbenzanthracene-induced mammary carcinoma of the rat to a response pattern similar to that of the antiestrogen zindoxifene. This suggests that the inhibition of transcription factor formation might be the common pathway for alkylphosphocholines and antihormones. Based on the experimental dose-response pattern, new clinical strategies for dose finding and response evaluation will have to be developed for inhibitors of signal transduction, such as alkylphosphocholines.

Key words: Alkylphosphocholines, Signal transduction, Antihormones, Drug development strategies

References

  1. Beckers T, Voegeli R (1994) Molecular targets of miltefosine. In: Hilgard P, Engel J (eds) Clinical aspects of miltefosine and its topical formulation Miltex®. Drugs Today 30 [Suppl B]
  2. Evans RM (1988) The steroid and thyroid hormone receptor superfamily. Science 240:889–895 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gibbs JB, Cliff A (1994) Pharmaceutical research in molecular oncology. Cell 79:193–198 [DOI] [PubMed] [Google Scholar]
  4. Grunicke H (1995) Signal transduction mechanisms in cancer. Landes, Austin [DOI] [PubMed] [Google Scholar]
  5. Hilgard P, Stekar J, Wuttke W, Elliger M, Holtei W (1988) Comparative pharmacology of zindoxifene and tamoxifen. Prog Cancer Res Ther 35:369–373 [Google Scholar]
  6. Hilgard P, Stekar J, Voegeli R, Harleman JH (1992) Experimental therapeutic studies with miltefosine in rats and mice. In: Eibl H, Hilgard P, Unger C (eds) Alkylphosphocholines: new drugs in cancer therapy. Prog Exp Tumor Res 34: 98–115 [DOI] [PubMed]
  7. Michna H, Schneider MR, Nishino Y, El Etrebi MF (1989) The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death. J Steroid Biochem 34:447–453 [DOI] [PubMed] [Google Scholar]
  8. Minana MD, Felipo V, Grisolia S (1990) Inhibition of protein kinase C induces differentiation in Neuro-2a-cells. Proc Natl Acad Sci USA 87:4335–4339 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Reissmann T, Engel J, Kutscher B, Bernd M, Hilgard P, Peukert M, Szelenyi I, Reichert S, Gonzalez-Barcena D, Nieschlag E, Comaru-Schally AM, Schally AV (1994) Cetrorelix. Drugs Future 19:228–237 [Google Scholar]
  10. Unger C (1996) Current concepts of treatment in medical oncology: new anticancer drugs. J Cancer Res Clin Oncol 122:189–198 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES